RegulatoryGuideline · draft

FDA publishes new and revised draft product-specific guidances on bioequivalence for generics

🇺🇸 FDA · Fri 20 Nov 2026

The US regulator has announced further draft and revised draft product-specific guidances, with a 60-day comment window running to 19 January 2027.

The US Food and Drug Administration (FDA) has announced the availability of additional draft and revised draft product-specific guidances for industry. The notice was published in the Federal Register on 20 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official guideline text: FDA ↗

Article written by VigiEye from the official source (FDA). AI-assisted; check the source before acting.